pharmaphorum April 22, 2024
Bristol-Myers Squibb has shored up manufacturing of its CAR-T therapies, tapping into capacity at contract manufacturer Cellares that will be used to supply patients in the US, Europe, and Japan.
The deal – worth up to $380 million – comes as BMS is preparing to further the rollout of its CAR-Ts Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel), used to treat haematological cancers, with a pipeline of others in clinical development. The pharma giant is already an investor in Cellares, contributing to a $255 million Series C financing last year.
Cellares was formed specifically to improve the efficiency of cell therapy production, which currently requires expensive and time-consuming manufacturing processes that can take weeks to complete. The startup applies robotics...
Today's Sponsors
Today's Sponsor